Clinical trial

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's…

NCT00199420 · Kyowa Kirin, Inc., Industry · Completed

Key facts

NCT number NCT00199420
Title A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
Official title A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on…
Lead sponsor Kyowa Kirin, Inc., Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Parkinson's Disease
Intervention type Drug
Interventions Istradefylline (KW-6002)
Enrollment 580
Start date Jul 1, 2004
Primary completion Nov 1, 2005
Completion Dec 1, 2005
First posted Sep 20, 2005
Last update posted Apr 25, 2024
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies